Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
AssigneeCelera Corporation
InventorsDov SHIFFMAN, Michele CARGILL, James J. DEVLIN
Life of this patent
Estimating the term…
Abstract
The present invention is based on the discovery of genetic polymorphisms that are associated with coronary heart disease, and in particular MI, and response to drug treatment. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
Claims29
A method of determining whether a human has an altered risk for myocardial infarction, comprising testing nucleic acid from said human for the presence or absence of a polymorphism selected from the group consisting of the polymorphisms at position 101 of any one of the nucleotide sequences of SEQ ID NOS:1663-17,275 or its complement, wherein the polymorphism indicates an altered risk for myocardial infarction.
A method of identifying a human having an altered risk for myocardial infarction, comprising testing nucleic acid from said human for the presence or absence of a first polymorphism which is in linkage disequilibrium with a second polymorphism, wherein the second polymorphism is selected from the group consisting of the polymorphisms at position 101 of any one of the nucleotide sequences of SEQ ID NOS:1663-17,275 or its complement, and wherein the first polymorphism identifies said human as having an altered risk for myocardial infarction.
A method for reducing risk of myocardial infarction in a human, the method comprising administering to said human an effective amount of a therapeutic agent, said human having been identified as having an increased risk for myocardial infarction due to the presence or absence of a polymorphism selected from the group consisting of the polymorphisms at position 101 of any one of the nucleotide sequences of SEQ ID NOS:1663-17,275 or its complement.
Dependencies are inferred from the claim text.